On Aug. 3, 2020, members of the COVID R&D Alliance AbbVie, Amgen and Takeda Pharma announced the first patients enrolled in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial.

The I-SPY COVID Trial evaluated the efficacy of cenicriviroc, a chemokine (CCR2 and CCR5) dual-receptor antagonist, Otezlaﾮ (apremilast), a PDE4 inhibitor, and Firazyrﾮ (icatibant injection), a bradykinin B2 receptor antagonist in severely ill, hospitalized COVID-19 patients who require high-flow oxygen.